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A B S T R A C T
We established three iPSC lines from postmortem-cultured fibroblasts derived following the sudden unexpected death of an 8-year-old girl with Lennox-Gastaut
syndrome, who turned out to have the R551H-mutant STXBP1 gene. These iPSC clones showed pluripotent characteristics while retaining the genotype and de-
monstrated trilineage differentiation capability, indicating their utility in disease-modeling studies, i.e., STXBP1-encephalopathy. This is the first report on the
establishment of iPSCs from a sudden death child, suggesting the possible use of postmortem-iPSC technologies as an epoch-making approach for precise identifi-
cation of the cause of sudden death.
Resource table.
Unique stem cell lines identifier IMSUTi001-A
IMSUTi001-B
IMSUTi001-C
Alternative names of stem cell lines TkSSD1#AA (IMSUTi001-A)
TkSSD1#AB (IMSUTi001-B)
TkSSD1#AM (IMSUTi001-C)
Institution The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Division of Forensic Pathology and Science, Nagasaki University School of Medicine, Nagasaki, Japan
Contact information of distributor Takuma Yamamoto, tk-yamamoto@hyo-med.ac.jp
Takashi Okumura, tokumura@ims.u-tokyo.ac.jp
Type of cell lines iPSC
Origin Human
Cell source Skin fibroblasts
Clonality Clonal
Method of reprogramming Transgene free, Sendai virus vector
Multiline rationale Isogenic clones
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STXBP1 encephalopathy is a hereditary disorder causing various
phenotypes of epilepsy, sometimes leading to sudden unexpected death
in epilepsy. The established iPSC lines retain the heterozygous R551H-
STXBP1 genotype. Neuronal cells differentiated from them are expected
to verify the connection between the genotype and the pathology in
STXBP1 encephalopathy.
Resource details
STXBP1 encephalopathy is a hereditary disorder causing various
phenotypes such as Lennox-Gastaut syndrome and Ohtahara syndrome,
sometimes leading to sudden unexpected death in epilepsy (SUDEP)
(Stamberger et al., 2016). The patient in this study is an 8-year-old girl,
found dead suddenly and unexpectedly. At postmortem examination
the R551H-STXBP1 gene variant was detected as a heterozygous state
(Supplementary Fig. 1). This cell line can offer a useful resource to
investigate pathogenic mechanisms in STXBP1 encephalopathy
(Table 1).
Postmortem cultured fibroblasts were reprogrammed by Sendai
virus vector containing four Yamanaka factor genes. Written informed
consent was obtained from the family. We succeeded in generating
three clones (#1, #2, and #3) of induced pluripotent stem cells (iPSCs),
each showing a typical pluripotent cell colony-like appearance
(Fig. 1A). STR analysis revealed that the original fibroblasts and iPSCs
were genetically identical. All clones are confirmed to be mycoplasma-
free (Supplementary Fig. 2). The iPSC clones expressed both TRA-1-60
and TRA-1-81 pluripotency-associated markers (Fig. 1B). Flow cyto-
metric analysis revealed expression of pluripotency-associated cell
surface antigens SSEA4 (Fig. 1C). By quantitative gene expression
analysis, all clones exhibited expression of the OCT4 and NANOG
pluripotent marker genes (Fig. 1D). Furthermore, all iPSC clones were
shown to be capable of 3 germ layer differentiation, as shown in Fig. 1E.
Karyotype analysis showed some abnormalities in clones #1 and #3,
but none in clone #2 (Fig. 1F, Table 2). Most importantly, all iPSC
clones retained the R511H-heterozygous STXBP1 variant genotypes, as
in the original fibroblasts and patient blood cells (Fig. 1G).
Here, we propose the possibility of new application with the use of
iPSCs in a case of sudden unexpected death in childhood. The cause of
SUDEP is yet uncovered, for diagnosis of these conditions or diseases
requires analysis of living cells, but viable cells generally cannot be
derived from postmortem samples obtained at autopsy because of
postmortem changes. Applying postmortem iPSC technology would
enable recreation of lifetime conditions even in the postmortem period
and discovery of inherited functional diseases (Hjelm et al., 2011). To
the best of our knowledge, this represents the first “Revival autopsy” of
utilizing iPSCs derived from a sudden death patient. As iPSCs derived
postmortem retained the heterozygous R551H-STXBP1 genotype, neu-
ronal cells differentiated from them are expected to show cellular ab-
normalities, which should allow verification of the connection between
the genotype and the pathology, helping the diagnosis of the cause of
sudden death in this case.
Materials and methods
Fibroblast culture
Dermis was cut at autopsy of an 8-year-old girl with Lennox-Gastaut
syndrome and cultured as previously described (Yamamoto et al.,
2012).
Extraction of genomic DNA
Genomic DNA was isolated from blood leukocytes, which were also
obtained at autopsy, and frozen fibroblasts using a QIAamp DNA Mini
Kit (Qiagen).
Next-generation sequencing
A TruSight One sequencing panel was used and sequencing was
performed on a MiSeq System, using Variant Studio version 2.2.3
software (all Illumina).
Establishment of iPSCs and cell culture
The iPSCs were established in a similar manner to that previously
described (Nishimura et al., 2017). A newer version of the Sendai virus
vector (developed by Mahito Nakanishi, unpublished) was used, that
could deliver a single-stranded RNA genome containing four Yamanaka
factor genes into somatic cells. Fibroblasts were infected with the
Sendai virus vector, seeded on iMatrix-511 (Takara Bio)-coated 6-well
plates in StemFit AK02N medium (REPROCELL), followed by expansion
culture of picked-up colonies. All iPSC lines were maintained at 37°C,
5% CO2 on vitronectin (VTN-N, Gibco)-coated 6-well plates in Essential
8™ (E8) medium (Gibco) with daily media changes. For passaging, cells
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
TkSSD1#AA (IMSUTi001-A) TkSSD1-#1 Female 8 Asian CGC/CAC STXBP1 encephalopathy
TkSSD1#AB (IMSUTi001-B) TkSSD1-#2 Female 8 Asian CGC/CAC STXBP1 encephalopathy
TkSSD1#AM (IMSUTi001-C) TkSSD1-#3 Female 8 Asian CGC/CAC STXBP1 encephalopathy
Gene modification Yes
Type of modification Congenital
Associated disease STXBP1 encephalopathy
Gene/locus STXBP1/9q34.11 (c.1652G>A)
Method of modification Not applicable
Name of transgene or resistance Not applicable
Inducible/constitutive system Not applicable
Date archived/stock date 2018/6/28
Cell line repository/bank https://hpscreg.eu/cell-line/IMSUTi001-A
https://hpscreg.eu/cell-line/IMSUTi001-B
https://hpscreg.eu/cell-line/IMSUTi001-C
Ethical approval Written informed consent obtained from the family
Ethics Committee approval obtained by the Nagasaki University Graduate School of Medicine (15062620 and 150622325)
and the Institute of Medical Science, University of Tokyo (#25-3-0701 and #30-8-A0522).
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(~50% confluent) were dissociated with 0.5mM EDTA in PBS at 37°C,
5min (Invitrogen) in PBS, and split to 1:3–1:5 every 3–4 days.
Mycoplasma detection
All clones were confirmed to be mycoplasma-free, using the
MycoAlert™ Mycoplasma Detection Kit and MycoAlert™ Assay Control
Kit (Lonza). Images of iPSC colonies were captured with a Leica
DMI3000B system (Leica).
Immunofluorescence staining
Live iPSC colonies in 48-well culture plates were first incubated
with Hoechst 33342 (ThermoFisher Scientific) to counterstain the nu-
clei. One day later, iPSC colonies were then directly stained for 90min
at 37°C with the antibodies against TRA-1-60 or TRA-1-81 diluted in E8
medium (Table 3). After washing with PBS, fluorescence images were
captured with an Eclipse Ti microscope system (Nikon). Images were
edited using ImageJ (NIH) or GIMP2.10 (https://www.gimp.org/).
Flow cytometry
Cells harvested with Accutase (STEM CELL Technologies) were in-
cubated for 10min at 4°C with either anti-SSEA4 or isotype control
antibody (Table 3) diluted in PBS containing 1% fetal bovine serum
(Nichirei Biosciences). Data were acquired using a fluorescence-acti-
vated cell sorting Aria II sorter (BD Biosciences) and analyzed using
FlowJo X software (Tree Star).
Trilineage differentiation
To analyze the capability of iPSCs to differentiate into three germ
layers, in vitro differentiation was performed using the STEMdiff™
Trilineage Differentiation Kit (STEM CELL Technologies) according to
the instructions from the manufacturer. Marker genes analyzed were
paired box 6 (PAX6), SRY-box 17 (SOX17), Foxhead box A2 (FOXA2), T-
box transcription factor T (or Brachyury) (TBXT), and neural cell ad-
hesion molecule (NCAM).
Fig. 1. Characterization of three iPSC clones to confirm their utility in disease-modeling studies. (A) Phase contrast images of three iPSC clones (#1, #2, and #3)
showing typical pluripotent cell colony-like appearance. Scale bars = 500 μm. (B) Immunofluorescence images of three iPSC clones demonstrating expression of the
TRA-1-60 and TRA-1-81 pluripotency-associated markers (red). Hoechst staining of cell nuclei is shown in blue. Scale bars = 100 μm. (C) Flow cytometric analysis
reveals expression of the SSEA4 pluripotency-associated antigen on cell surface of virtually 100% of iPSCs. (D) Quantitative gene expression analysis. All clones in an
undifferentiated culture condition exhibit expression of the pluripotent marker genes, OCT4 and NANOG. (E) After cultivation under different conditions, selective
upregulation patterns are evident for each marker gene in accordance with the corresponding culture condition (with differentiation for an ectodermal lineage, blue;
an endodermal lineage, yellow; a mesodermal lineage, red) in all the iPSC clones. (F) Karyotype analysis shows some abnormalities in clones #1 (1 in 20 analytes)
and #3 (all 20 analyses), but none in clone #2. Detailed information is in Table 1. (G) Sanger sequencing results showing that all iPSC clones retain the R511H-
heterozygous STXBP1 variant genotype, as in the original fibroblasts and patient blood cells (Supplementary Figure 1).
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RT-qPCR
Total RNA was isolated from iPSCs either before or after differ-
entiation, using the RNeasy® Mini Kit (Qiagen). Complementary DNA
(cDNA) was synthesized using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). To quantify the pluripotency
markers octamer-binding transcription factor 4 (OCT4) and NANOG
expression, multiplex TaqMan real-time PCR analysis was conducted
using the Eagle Taq Master Mix with ROX (Roche). Universal probes
#34 and #69 (Roche) were used for labeling the OCT4 and NANOG
products, respectively. The Human G6PD Assay (Roche) was used for
quantifying the reference gene. The relative expression of OCT4 and
NANOG was evaluated with reference to their expression levels in our
standard hiPSC line TkDA3-4 (TkDA) previously established from a
healthy donor (Takayama et al., 2010). Quantification of differentiation
markers was conducted using a real-time PCR SYBR Green method with
the THUNDERBIRD® SYBR qPCR Mix (Toyobo). Expression of the genes
was normalized to G6PD. All the real-time PCR analyses were per-
formed using a CFX96 C1000™ thermal cycler (Bio-Rad). Relative ex-
pression was calculated by the ΔΔCt method with CFX™ Manager
software (Bio-Rad). Primers used are listed in Table 3.
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1A
Phenotype Qualitative analysis:
immunocytochemistry
Positive staining for pluripotency markers: TRA-1-60 and TRA-1-81 Fig. 1B
Quantitative analysis: flow cytometry ~100% cells showing high-level expression of SSEA4 Fig. 1C
Quantitative RT-qPCR Expression of pluripotency markers: OCT4 and NANOG Fig. 1D
Genotype Karyotype (G-banding), resolution
300–500
#1: 46,XX [19]; 46,XX, add(1)(p36.3),add(8)(q11.2) [1] Fig. 1F
#2: 46,XY [20]
#3: 46,XY,add(13)(p11.2) [20]
Identity Microsatellite PCR N/A N/A
STR analysis 10 loci tested, all matched Available with the authors
Mutation analysis Sanger sequencing Heterozygous D551H-STXBP1 (c.1652G>A) Fig. 1G, Supplementary
Fig. 1
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Negative by MycoAlert™ Mycoplasma detection kit Supplementary Fig. 2
Differentiation potential Directed differentiation Expression of lineage markers confirmed after directed differentiation:
ectoderm (PAX6), mesoderm (TBXT, NCAM), and endoderm (SOX-17,
FOXA2).
Fig. 1E
Donor screening HIV 1+2, Hepatitis B, Hepatitis C Tested during autopsy and negative Available with the authors
Genotype additional info Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency marker (flow cytometry) Mouse anti-SSEA4, APC-conjugated 1:200 Biolegend cat. # 330418, RRID:AB_2616819
Isotype control (flow cytometry) Mouse IgG3, kappa, Alexa Fluor 647-conjugated 1:2000 Biolegend cat. # 401321, RRID:AB_10683445
Pluripotency markers Mouse anti-TRA-1-60, NL(NorthernLightsTM)557-conjugated
(MAB4770)
1:50 R&D Systems cat. # NLLC4770R, RRID:AB_2773722
Mouse anti-TRA-1-81, NL(NorthernLightsTM)493-conjugated
(MAB8495)
1:50 R&D Systems cat. # NLLC16581G, RRID:AB_2773721
Primers
Target Forward/Reverse primer (5′-3′)




House-keeping gene (qRT-PCR) G6PD Primers from the Universal ProbeLibrary Human G6PD Assay (Roche)
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Karyotype analysis
Standard G-banded karyotyping was conducted by the NIHON Gene
Research Laboratories (passage 8 for clones #1 and #2, passage 10 for
clone #3).
Identification and verification of iPSCs
The identities of iPSCs and fibroblasts were confirmed by STR
analysis and Sanger sequencing. Genomic DNA was isolated from iPSCs
and fibroblasts using QIAamp DNA Mini Kit (Qiagen) in accordance
with the manufacturer's standard methods. STR analysis was performed
at TAKARA Bio using the GenePrint® 10 System (Promega).
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